<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149081</url>
  </required_header>
  <id_info>
    <org_study_id>102688</org_study_id>
    <nct_id>NCT03149081</nct_id>
  </id_info>
  <brief_title>A &quot;Window Trial&quot; on Boswellia for Breast Cancer and Colon Cancer Primary Tumors</brief_title>
  <official_title>A &quot;Window Trial&quot; on Boswellia, an Extract From Frankincense, for Breast and Colon Cancer Primary Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nancy Demore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral administration of Boswellia causes
      biological changes in primary tumors of breast cancer and colon cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine whether oral administration of Boswellia serrata causes biological changes
      related to angiogenesis (CD31), apoptosis (DNA fragmentation), and cell proliferation (Ki67)
      in primary tumors of breast or colon cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tumor proliferation rate</measure>
    <time_frame>up to 56 days</time_frame>
    <description>Change in tumor proliferation rate will be based on Ki67, CD31 and TUNEL assays in biopsies pre and post treatment with boswellia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events reported</measure>
    <time_frame>up to 84 days</time_frame>
    <description>Safety data will be tabulated by type and grade of adverse event and will use CTCAE v. 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tumors analyzed through immunohistochemistry</measure>
    <time_frame>up to 56 days</time_frame>
    <description>Additional changes in tumors as a result of boswellia intake will be analyzed through immunohistochemistry on paraffin-embedded tumors.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Boswellia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Boswellia will be given at 800mg by mouth three times a day, immediately after each meal. Boswellia will be given from the time surgical resection is scheduled until the night before surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boswellia</intervention_name>
    <description>Boswellia is an extract from frankinscense</description>
    <arm_group_label>Boswellia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed ductal carcinoma in situ (DCIS) or invasive breast cancer
             (stages I, II, or III) with primary tumor(s) â‰¥ 1cm on mammogram, ultrasound, MRI, or
             physical exam or histologically confirmed adenocarcinoma of the colon, stages I, II or
             III.

          -  18 years of age or older

          -  Subject must understand risks and benefits of the protocol and be able to give
             informed consent

          -  Females of child-bearing potential must agree to use an approved form of birth control
             and to have a negative pregnancy test result before and throughout the study

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate hematologic and end organ function

          -  Ability and capacity to comply with the study and follow-up procedure

        Exclusion Criteria:

          -  Patients undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy

          -  Individuals with end-stage kidney disease and/or grade II liver dysfunction

          -  Subject has active or history of deep vein thrombosis (DVT)

          -  Subject has a history of coagulopathies or hematological disorders

          -  Individuals who are pregnant or are lactating during the study

          -  Patients already taking drugs known to be 5-lipoxygenase inhibitors (Refer to section
             5)

          -  Individuals taking drugs that interact with OATP1B3 (an anion transporter), MRP2 (a
             multidrug resistant protein), and/or P-Glycoprotein (P-Gp) (Refer to section 5.)

          -  Individuals taking anti-coagulants or platelet inhibitors (Refer to section 5)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Klauber-DeMore, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devin Gibson</last_name>
      <phone>843-792-9321</phone>
      <email>hcc-clinical-trials@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Nancy Demore</investigator_full_name>
    <investigator_title>Medical Director, MUSC Breast Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

